Low-dose capecitabine plus trastuzumab as first-line treatment in patients 75 years of age or older with HER2-positive advanced gastric cancer: a pilot study
- Authors
- Kim, Young Saing; Sym, Sun Jin; Baek, Min Young; Park, Inkeun; Hong, Junshik; Ahn, Hee Kyung; Park, Jinny; Cho, Eun Kyung; Lee, Woon Ki; Chung, Min; Kim, Hyung-Sik; Lee, Jae Hoon; Shin, Dong Bok
- Issue Date
- Dec-2015
- Publisher
- SPRINGER
- Keywords
- Gastric cancer; HER2; Trastuzumab; Capecitabine; Elderly
- Citation
- CANCER CHEMOTHERAPY AND PHARMACOLOGY, v.76, no.6, pp.1267 - 1272
- Journal Title
- CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Volume
- 76
- Number
- 6
- Start Page
- 1267
- End Page
- 1272
- URI
- https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/9871
- DOI
- 10.1007/s00280-015-2881-x
- ISSN
- 0344-5704
- Abstract
- Single-agent chemotherapy is considered a good and safe treatment option for elderly patients with advanced gastric cancer (AGC). We investigated the efficacy and safety of trastuzumab plus low-dose capecitabine in elderly patients with previously untreated human epidermal growth factor receptor 2 (HER2)-positive AGC. Patients aged 75 years or older with tumors having HER2 overexpression defined as either immunohistochemistry (IHC) 3+ or IHC 2+ and in situ hybridization-positive were eligible for inclusion. Patients received capecitabine (1000 mg/m(2)) orally twice daily on days 1-14 and trastuzumab (8 mg/kg for cycle 1, followed by 6 mg/kg) intravenously on day 1 of a 21-day cycle. The primary endpoint was progression-free survival (PFS). Twenty patients were enrolled. The median age was 79 years (range 75-91). Nine patients (45 %) had ECOG performance status 2. Median PFS was 5.2 months (95 % CI 1.9-8.4 months), and median overall survival was 9.3 months (95 % CI 4.0-14.6 months). The confirmed response rate was 40 % (95 % CI 19-64 %) with disease control rate of 80 %. Grade 3-4 toxicities were anorexia (10 %), fatigue (5 %), stomatitis (5 %), and anemia (5 %). No treatment-related deaths or symptomatic congestive heart failure were observed. Low-dose capecitabine plus trastuzumab is effective and well tolerated in elderly patients with HER2-positive AGC.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - 의과대학 > 의학과 > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/9871)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.